Epstein-Barr virus and its possible role in the pathogenesis of B-cell lymphomas

Critical Reviews in Oncology/Hematology

Volumn 25, Issue 2, 1997, Pages 127-138

  Oudejans, Joost J ^a   Jiwa, N Mehdi ^a,b   Van den Brule, Adriaan J C ^a   Meijer, Chris J L M ^a,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Location Alkmaar   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL LYMPHOMA; EPSTEIN BARR VIRUS; HUMAN; REVIEW;

HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA, B-CELL; TUMOR VIRUS INFECTIONS;

EID: 0030889438     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(97)00233-3     Document Type: Review

References (133)

1. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1:702-703, 1964.
2. Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS. Epstein - Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 310:1225-1230, 1984.
3. Wolf H, Haus M, Wilmes E. Persistence of Epstein - Barr virus in the parotid gland. J Virol 51:795-798, 1984.
4. Brown NA, Liu C, Carcia CR, Wang YF, Griffith A, Sparkes RS, Calame KL. Clonal origins of lymphoproliferative disease induced by Epstein - Barr virus. J Virol 58:975-978, 1986.
5. Brown NA, Smith D, Miller G, Niederman J, Liu C, Robinson J. Infectious mononucleosis: A polyclonal B cell transformation in vivo. J Infect Dis 150:517-512, 1984.
6. Raab-Traub N. Epstein - Barr virus and nasopharyngeal carcinoma. Semin Cancer Biol 3, 297-307, 1992.
7. Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, Anderson KC, Ritz J, Shapiro RS, Rickinson AB, Kieff E, Cohen JL. Expression of Epstein - Barr virus transformation associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 321:1080-1085, 1989.
8. Hamilton-Dutoit SJ, Pallesen G, Franzmann MB, Karkov J, Black F, Skinhoj P, Pedersen C. AIDS-related lymphoma. Histopathology, immunephenotype and association with Epstein - Barr virus as demonstrated by in-situ nucleic acid hybridisation. Am J Pathol 138:149-163, 1991.
9. Howe JG, Steitz JA. Localization of Epstein - Barr virus-encoded small RNAs by in situ hybridization. Proc Natl Acad Sci USA 83:9006-9010, 1984.
10. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein - Barr viral genomes in Reed Sternberg cells of Hodgkin's disease. N Engl J Med 320:502-506, 1989.
11. Hamilton-Dutoit SJ, Pallesen G. Detection of Epstein - Barr virus small RNAs in routine paraffin sections using non-isotopic RNA/RNA in situ hybridization. Histopathology 25:101-111, 1994.
12. Hummel M, Anagnostopoulos I, Korbjuhn P, Stein H. Epstein - Barr virus in B-cell non-Hodgkin's lymphomas: Unexpected infection patterns and different infection incidence in low and high-grade types. J Pathol 175:263-271, 1995.
13. De Bruin PC, Jiwa NM, Oudejans JJ, van Heerde P, Sabourin JC, Csanaky G, Gaulard Ph, Noorduyn LA, Willemze R, Meijer CJLM. Presence of Epstein - Barr virus in extranodal T-cell lymphomas: Differences in relation to site. Blood 83:1612-1618, 1994.
14. De Bruin PC, Jiwa NM, van der Valk P, van Heerde P, Meijer CJLM. Detection of Epstein - Barr virus nucleic acid sequences and protein in nodal T-cell lymphomas: Relation between latent membrane protein 1 positivity and clinical course. Histopathology 23:509-518, 1993.
15. Korbjuhn P, Anagnostopoulos I, Hummel M, Tremann M, Dallenbach F, Parwaresch MR, Stein H. Frequent latent Epstein - Barr virus infection of neoplastic T cells and bystander B cells in human immunedeficiency virus negative European peripheral pleomorphic T-cell lymphomas. Blood 82:217-223, 1993.
16. Meijer CJLM, Jiwa NM, Dukers DF, Oudejans JJ, de Bruin PC, Walboomers JMM, VandenBrule AJC. Epstein - Barr virus and human T-cell lymphomas. Semin Cancer Biol 7:191-196, 1996.
17. Hamilton-Dutoit SJ, Rea D, Raphael M, Sandvej K, Delecluse HJ, Gisselbrecht C, Marelle L, van-Krieken HJ, Pallesen G. Epstein - Barr virus-latent gene expression and tumour cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am J Pathol 143:1072-1085, 1993.
18. Knowles DM, Dalla-Favera R. AIDS-associated malignant lymphoma. In: Broder S, Merigan T, Bolognesi D, eds. Textbook of AIDS Medicine. Baltimore: Williams and Wilkins, 1994; 431-464.
19. Rea D, Fourcade C, Leblond V, Rowe M, Joab I, Edelman L, Bitker M, Gandjbakhch I, Suberbielle C, Farcet J, Raphael M. Patterns of Epstein - Barr virus latent and replicative gene expression in Epstein - Barr virus B cell lymphoproliferative disorders after organ transplantation. Transplantation 58:317-324, 1994.
20. Raab Traub N, Flynn K. The structure of the termini of the Epstein - Barr virus as a marker of clonal proliferation. Cell 47:883-889, 1986.
21. Neri A, Barriga F, Knowles DM, Neequaye J, Magrath IT, Dalla-Favera R. Epstein - Barr virus infection precedes clonal expansion in Burkitt's and AIDS-associated lymphoma. Blood 77:1092-1095, 1991.
22. Kaplan MA, Ferry JA, Harris NL, Jacobson JO. Clonal analysis of posttransplant lymphoproliferative disorders, using both episomal Epstein - Barr virus and immunoglobulin genes as markers. Am J Clin Pathol 101(5):590-596, 1994.
23. Cleary ML, Nalesnik MA, Shearer WT, Sklar J. Clonal analysis of transplant-associated lymphoproliferations based on the structure of the genomic termini of the Epstein - Barr virus. Blood 72:349-352, 1988.
24. Starzl TE, Nalesnik MA, Prter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal TJ, Hakala TR, Shaw BJ, Hardesty RL, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1:583-587, 1984.
25. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, Young JW, Kernan NA, O'Reilly RJ. Infusion of donor leukocytes to treat Epstein - Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330:1185-1191, 1994.
26. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE. Use of gene modified virus-specific T lymphocytes to control Epstein - Barr virus related lymphoproliferation. Lancet 345:9-13, 1995.
27. Zur Hausen H, Schulte-Holthausen H, Klein G, et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228: 1056-1058, 1970.
28. Pagano JS, Huang CH, Levine PH. Absence of Epstein - Barr viral DNA in American Burkitt's lymphoma. N Engl J Med 289:1395-1399, 1973.
29. Razzouk BI, Srinivas S, Sample CE, Singh V, Sixbey JW. Epstein - Barr virus DNA recombination and loss in sporadic Burkitt's lymphoma. J Infect Dis 173:529-535, 1996.
30. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H, Rickinson AB. Differences in B-cell growth phenotype reflect novel patterns of Epstein - Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 6:2743-2751, 1987.
31. Shimizu N, Tanabe-Tochikura A, Kuroiwa Y, Takada K. Isolation of Epstein - Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J Virol 68(9):6069-6073, 1994.
32. Wilson JB, Levine AJ. The oncogenic potential of Epstein - Barr virus nuclear antigen-1 in transgenic mice. Curr Top Microbiol Immunol 182:374-384, 1992.
33. Srinivas SK, Sixbey JW. Epstein - Barr virus induction of recombinase-activating genes RAG1 and RAG2. J Virol 69:8155-8158, 1995.
34. Loke SL, Ho F, Srivastava G, Fu KH, Leung B, Liang R. Clonal Epstein - Barr virus in T-cell rich lymphomas of B or probable B lineage. Am J Pathol 140:981-989, 1992.
35. Kieff E, Liebowitz D. Epstein - Barr virus and its replication. In: Fields BN, Knipe DM, eds. Virology. New York: Raven press, 1990; 1889-1920.
36. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, Hatfull G, Hudson GS, Satchwell SC, Seguin C, Tuffnell PS, Barrell BG. DNA sequence and expression of the B95.8 Epstein - Barr virus genome. Nature 310:207-211, 1984.
37. Miller G. Epstein - Barr virus. In: Fields BN, Knipe DM, eds. Virology. New York: Raven press, 199; 1921-1958, 1990.
38. Gerber P, Monroe JH. Studies on leukocytes growing in continuous culture derived from normal human donors. J Natl Cancer Inst 40:855-866, 1968.
39. Gratama JW, Oosterveer MAP, Zwaan FE, Lepoutre J, Klein G, Ernberg I. Eradication of Epstein - Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sci USA 85:8693-8696, 1988.
40. Miyashita EM, Yang B, Lam KM, Crawford DH, Thorley-Lawson DA. A novel form of Epstein - Barr virus latency in normal B-cells in vivo. Cell 80:593-601, 1995.
41. Strauch B, Siegel N, Andrews L, Miller G. Oropharyngeal excretion of Epstein - Barr virus by renal transplant recipients and other patients treated with immunosuppressive drugs. Lancet 1:234-237, 1987.
42. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Lisse I, Ralfkiaer E, Sandvej K, Young LS. Expression of Epstein - Barr virus replicative proteins in AIDS-related non-Hodgkin's lymphoma cells. J Pathol 165:289-299, 1991.
43. Rea D, Delecluse HJ, Hamilton-Dutoit SJ, Marelle L, Joab I, Edelman L, Finet JF, Raphael M. Epstein - Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non-Hodgkin's lymphomas. French Study Group of Pathology for HIV-associated Tumors. Ann Oncol 5(Suppl 1):S113-S116, 1994.
44. Henderson E, Miller G, Robinson J, Heston L. Efficiency of transformation of lymphocytes by Epstein - Barr virus. Virology 76:152-163, 1977.
45. Pearson GR, Luka J, Petti L, Sample J, Birkenbach M, Braun D, Kieff E. Identification of an Epstein - Barr virus early gene encoding a second component of the restricted early antigen complex. Virology 160:151-161, 1987.
46. Austin PJ, Flemington E, Yandawa CN, Strominger JL, Speck SH. Complex transcription of the Epstein - Barr virus BamH1 fragment H rightward open reading frame 1 (BHRF1) in latently and lytically infected B lymphocytes. Proc Natl Acad Sci USA 85:3678-3682, 1988.
47. Oudejans JJ, Vandenbrule AJC, Jiwa NM, de Bruin PC, Ossenkoppele GJ, van der Valk P, Walboomers JMM, Meijer CJLM. BHRF1, the Epstein - Barr virus (EBV) homologue of the bcl-2 protooncogene, is transcribed in EBV associated B-cell lymphomas and in reactive lymphocytes. Blood 86:1893-1902, 1995.
48. Miyazaki I, Cheung RK, Dosch HM. Viral Interleukin-10 is critical for the induction of B-cell growth transformation by Epstein - Barr virus. J Exp Med 178:439-447, 1993.
49. Rowe M, Lear AL, Croom-Carter D, Davies AH, Rickinson AB. Three pathways of Epstein - Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol 66:122-131, 1992.
50. Gratama JW, Zutter MM, Minarovits J, Oosterveer MA, Thomas ED, Klein G, Ernberg I. Expression of Epstein - Barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients. Int J Cancer 47(2): 188-192, 1991.
51. Deacon EM, Pallesen G, Nieboditek G, Crocker J, Brooks L, Rickinson AB, Young LS. Epstein - Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med 177:339-349, 1993.
52. Brooks L, Yao QY, Rickinson AB, Young LS. Epstein - Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 66:2689-2697, 1992.
53. Minarovits J, Hu LF, Marcsek Z, Minarovits Kormuta S, Klein G, Ernberg I. RNA polymerase III-transcribed EBER 1 and 2 transcription units are expressed and hypomethylated in the major Epstein - Barr virus-carrying cell types. J Gen Virol 73:1687-1692, 1992.
54. Brooks LA, Lear AL, Young LS, Rickinson AB. Transcripts from the Epstein - Barr virus BamHI A fragment are detectable in all three forms of virus latency. J Virol 67(6):3182-3190, 1993.
55. Oudejans JJ, Jiwa NM, Vandenbrule AJC, Grässer FA, Horstman A, Vos W, Klum PhM, van der Valk P, Walboomers JMM, Meijer CJLM. Detection of heterogeneous Epstein - Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders. Am J Pathol 147:923-933, 1995.
56. Qu L, Rowe DT. Epstein - Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J Virol 66:3715-3724, 1992.
57. Tierney RJ, Steven N, Young LS, Rickinson AB. Epstein - Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol 68(11):7374-7385, 1994.
58. Chen F, Zou J, di Renzo L, Winberg G, Hu I, Klein E, Klein G, Ernberg I. A subpopulation of normal B cells latently infected with Epstein - Barr virus resembling Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP-1. J Virol 69:3752-3758, 1995.
59. Vaux DL, Haecker G, Strasser A. An evolutionary perspective on apoptosis. Cell 76:777-779, 1994.
60. Weiss LM, Roger MD, Warnke RA, Sklar J, Cleary ML. Molecular analysis of the t(14; 18) chromosomal translocation in malignant lymphomas. N Engl J Med 317:1185-1189, 1987.
61. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83:5214-5218, 1986.
62. Ngan BY, Chen-Levy Z, Lawrence D, Weiss M, Warnke RA, Cleary ML. Expression in non-Hodgkin Lymphoma of the bcl-2 protein associated with the t(14-18) chromosomal translocation. N Engl J Med 318:1638-1644, 1988.
63. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and hybrid bcl-2/immunoglobulin transcript resulting from the t(14; 18) translocation. Cell 47:19-28, 1986.
64. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440-1443, 1985.
65. Hockenberry D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336, 1990.
66. Henderson S, Huen D, Rowe M, Dawson C, Johnson G, Rickinson A. Epstein - Barr virus-coded BHRF1 protein, a viral homologue of bcl-2, protects human B-cells from programmed cell death. Proc Natl Acad Sci USA 90:8479-8483, 1993.
67. Hengartner MO, Horvitz HR. C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell 76:665-676, 1994.
68. Neilan JG, Lu Z, Afonso CL, Kutish GF, Sussman MD, Rock DL. An African swine fever virus gene with similarity to the proto-oncogene bcl-2 and the Epstein - Barr virus gene BHRF1. J Virol 67:4391-4394, 1993.
69. Takayama S, Cazals-Hatem DL, Kitada S, Tanaka S, Miyashita T, Hovey LR 3d, Huen D, Rickinson A, Veerapandian P, Krajewski S, et al. Evolutionary conservation of function among mammalian, avian, and viral homologs of the Bcl-2 oncoprotein. DNA Cell Biol 13(7):679-692, 1994.
70. Yin X-M, Oltval ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369:321-323, 1994.
71. Oltval ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619, 1993.
72. Zhan Q, Fan S, Bae I, Guillouf C, Liebermann DA, O'Connor PM, Fornace AJ Jr. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 9(12):3743-3751, 1994.
73. Finke J, Fritzen R, Ternes P, Trivedi P, Bross KJ, Lange W, Mertelsmann R, Dolken G. Expression of bcl-2 in Burkitt's lymphoma cell lines: induction by latent Epstein - Barr virus genes. Blood 80:459-469, 1992.
74. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A. Induction of bcl-2 expression by Epstein - Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65(7): 1107-1115, 1991.
75. Murray PG, Swinnen U, Constandinou CM, Pyle JM, Carr TJ, Hardwick JM, Ambinder RF. BCL-2 but not its Epstein - Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders. Blood 87:706-711, 1996.
76. Chetty R, Kaklamanis L, Biddolph SC, Giatromanolaki A, Cary N, Stewart S, Gatter KC. Epstein - Barr virus latent membrane (LMP-1) and bcl-2 expression in Reed-Sternberg-like cells in post-transplant lymphoproliferative disorders. Histopathology 28:257, 1996.
77. Camilleri-Broet S, Davi F, Fenillard J, Bourgeois C, Seilhean D, Mauw JJ, Raphael M. High expression of latent membrane protein of Epstein - Barr virus and bcl-2 oncoprotein in acquired immunodeficiency syndrome related primary brain lymphomas. Blood 86:432-435, 1995.
78. Martin JM, Veis D, Korsmeyer SJ, Sugden B. Latent membrane protein of Epstein - Barr virus induces cellular phenotypes independently of expression of bcl-2. J Virol 67:5269-5278, 1993.
79. Khan G, Gupta RK, Coates PJ, Slavin G. Epstein - Barr virus infection and bcl-2 proto-oncogene expression: separate events in the pathogenesis of Hodgkin's disease? Am J Pathol 143:1270-1274, 1993.
80. Jiwa NM, Kanavaros P, Van der Valk P, Walboomers JMM, Horstman A, Vos W, Mullink H, Meijer CJLM. Expression of c-myc and bcl-2 oncogene products in Reed-Sternberg cells independent of the presence of Epstein - Barr virus. J Clin Pathol 46:211-217, 1993.
81. Jiwa NM, Oudejans JJ, Bai MC, Vandenbrule AJC, Horstman A, Wos W, van der Valk P, Kluin PhM, Walboomers JMM, Meijer CJLM. Expression of bcl-2 protein and transcription of the Epstein - Barr virus bcl-2 homologue BHRF-1 in Hodgkin's disease: implications for different pathogenic mechanisms. Histopathology 26:547-553, 1995.
82. Lu QL, Elia G, Lucas S, Thomas JA. Bcl-2 proto-oncogene expression in Epstein - Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer 53:29-35, 1993.
83. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodents cells. Cell 43:831-840, 1985.
84. Mann KP, Staunton D, Thorley Lawson DA. Epstein - Barr virus encoded protein found in plasma membranes of transformed cells. J Virol 55:710-715, 1985.
85. Kaye KM, Izumi KM, Kieff E. Epstein - Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 90(19):9150-9154, 1993.
86. Mosialos G, Birkenbach M, Yalamanchili R, Van Arsdale T, Ware C, Kieff E. The Epstein - Barr virus transforming protein LMP1 engages signalling proteins for the tumor necrosis factor receptor family. Cell 80(3):389-399, 1995.
87. Huen DS, Henderson SA, Croom-Carter D, Rowe M. The Epstein - Barr virus latent membrane protein 1 (LMP-1) mediates induction of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10:549-560, 1995.
88. Knecht H, Bachman E, Brousset P, Sandvej K, Nadal D, Bachman F, Odermatt BF, Delsol G, Pallesen G. Deletions within the LMP1 oncogene of Epstein - Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 82:2937-2942, 1993.
89. Knecht H, Martius F, Bachmann E, Hoffman T, Zimmermann DR, Rothenberger S, Sandvej K, Wegmann W, Hurwitz N, Odermatt BF, et al. A deletion mutant of the LMP1 oncogene of Epstein - Barr virus is associated with evolution of angioimmunoblastic lymphadenopathy into B immunoblastic lymphoma. Leukemia 9(3):458-465, 1995.
90. Sandvej K, Peh S-C, Storstein-Andresen B, Pallesen G. Idenification of potential hot spots in the carboxy-terminal part of the Epstein - Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: high frequency of a 30 bp deletion in Malaysian and Danisch peripheral T-cel lymphomas. Blood 84:4053, 1994.
91. Cohen JI, Wang F, Kieff E. Epstein - Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol 65(5):2545-2554, 1991.
92. Cohen JI, Picchio GR, Mosier DE. Epstein - Barr virus nuclear protein-2 is a critical determinant for tumor growth in SCID mice and for transformation in vitro. J Virol 66:7555-7559, 1992.
93. Wang F, Tsang SF, Kurilla MG, Cohen JI, Kieff E. Epstein - Barr virus nuclear antigen 2 transactivates latent membrane protein LMP-1. J Virol 64:3407-3416, 1990.
94. Middleton T, Gahn TA, Martin JM, Sugden B. Immortalizing genes of Epstein - Barr virus. Adv Virus Res 40:19-55, 1991.
95. Sinclair AJ, Palmero I, Peters G, Farrell PJ. EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein - Barr virus. EMBO J 13(14):3321-3328, 1994.
96. Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khna TA, Mosmann TR. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein - Barr virus gene BCRF1. Science 248:1230-1234, 1990.
97. Baiocchi RA, Ross ME, Tan JC, Chou CC, Sullivan L, Haldar S, Monne M, Seiden MV, Narula SK, Sklar J, et al. Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10. Blood 85(4):1063-1074, 1995.
98. Nakagomi H, Dolcetti R, Bejarano MT, Pisa P, Kiessling R, Masucci MG. The Epstein - Barr virus latent membrane protein-1 (LMP-1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer 57:240, 1994.
99. Masoud R, Zhang Y, Boud MW, Scadden DT, Mondgil T, Law RE, Kaplan MH, Jung B, Espina BM, Lunardi-Iskander Y, et al. Interleukin-10 is an autocrine growth factor for acquired immunodeficieny syndrome related B-cell lymphomas. Blood 85:3423-3430, 1995.
100. Szekely L, Selivanova G, Magnusson KP, Klein G, Wiman KG. EBNA-5, an Epstein - Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci USA 90:5455-5459, 1993.
101. Marx J. How p53 suppresses cell growth. Science 262:1644-1645, 1993.
102. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed J. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805, 1994.
103. Rowe D, Rowe M, Evan G, Wallace L, Rickinson B. Restricted expression of EBV latent genes and T-lymphocyte detected membrane antigen in Burkitt's lymphoma cells. EMBO J 5:2599-2607, 1985.
104. Sample J, Brooks L, Sample C, Young L, Rowe M, Gregory C, Rickinson AB, Kieff E. Restricted Epstein - Barr virus protein expression in Burkitt lymphoma is due to a different Epstein - Barr nuclear antigen 1 transcriptional initiation site. Proc Natl Acad Sci USA 88:6343-6347, 1991.
105. Rickinson AB, Moss DJ, Wallace LE, Rowe M, Misko IS, Epstein MA, Pope JH. Long term T-cell-mediated immunity to Epstein - Barr virus. Cancer Res 41:4218-4221, 1981.
106. Khanna R, Borrows S, Kurilla M, Jacob C, Misko I, Sculley T, Kieff E, Moss DJ. Localisation of Epstein - Barr virus cytotoxic T-cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 176:169-176, 1992.
107. Masucci MG, Ernberg I. Epstein - Barr virus: Adaptation to a life within the immune system. Trends in Microbiology 2:125-130, 1994.
108. Klein G. Epstein - Barr virus strategy in normal and neoplastic cells. Cell 77:791-793, 1994.
109. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, Kurilla MG, Masucci MG. Inhibition of antigen processing by the internal repeat region of the Epstein - Barr virus nuclear antigen-1. Nature 375:685-688, 1995.
110. Masucci MG, Stam NJ, Torsteinsdottir S, Neefjes JJ, Klein G, Ploegh HL. Allele-specific down-regulation of MHC class I antigens in Burkitt Lymphoma lines. Cell Immunol 120:396-400, 1989.
111. Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT. Epstein - Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci USA 81:4510-4516, 1984.
112. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A. Induction of bcl-2 expression by Epstein - Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65(7):1107-1115, 1991.
113. Chen F, Zou J, di Renzo L, Winberg G, Hu I, Klein E, Klein G, Ernberg I. A subpopulation of normal B cells latently infected with Epstein - Barr virus resembling Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol 69:3752-3758, 1995.
114. Gratama JW, Oosterveer MAP, Zwaan FE, Lepoutre J, Klein G, Ernberg I. Eradication of Epstein - Barr virus by allogeneic bone marrow transplantation: Implications for sites of viral latency. Proc Natl Acad Sci USA 85:8693-8696, 1988.
115. Miyashita EM, Yang B, Lam KM, Crawford DH, Thorley-Lawson DA. A novel form of Epstein - Barr virus latency in normal B cells in vivo. Cell 80(4):593-601, 1995.
116. Niedobitek G, Herbst H, Young LS, Brooks L, Masucci MG, Crocker J, Rickinson AB, Stein H. Patterns of Epstein - Barr virus infection in non-neoplastic lymphoid tissue. Blood 79:2520-2526, 1992.
117. Oudejans JJ, Dukers DF, Jiwa NM, Vandenbrule AJC, Grässer FA, de Bruin PC, Horstman A, Vos W, van Gorp J, Middeldorp JM, Meijer CJLM. Expression of Epstein - Barr virus (EBV) encoded nuclear antigen 1 (EBNA1) in benign and malignant EBV harbouring tissues. J Clin Pathol 49:897-902, 1997.
118. Kaplan MA, Ferry JA, Harris NL, Jacobson JO. Clonal analysis of posttransplant lymphoproliferative disorders, using both episomal Epstein - Barr virus and immunoglobulin genes as markers. Am J Clin Pathol 101:590-596, 1994.
119. Neri A, Barriga F, Knowles DM, Neequaye J, Magrath IT, Dalla-Favera R. Epstein - Barr virus infection precedes clonal expansion in Burkitt's and AIDS associated lymphoma. Blood 77:1092-1095, 1991.
120. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, Michler RE. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of post-transplantation lymphoproliferative disorders. Blood 85:552-565, 1995.
121. Limpens J, Stad R, Vos C, de Vlaam C, de Jong D, van Ommen GB, Schuuring E, Kluin PhM. Lymphoma-associated translocation t(14-18) in blood B-cells of normal individuals. Blood 85:2528-2536, 1995.
122. Schlaifer D, Brousset P, Attal M, Massip P, Payen C, Marchou B, Huguet F, Muller C, Laurant G, Pris J, Delsol G. BCL-2 proto-oncogene and Epstein - Barr virus latent membrane protein-1 expression in AIDS-related lymphomas. Histopathology 25:77, 1994.
123. De Jong D, Betsie MD, Voetdijk MH, Beverstock GC, van Ommen GB, Willemze R, Kluin PhM. Activation of the c-myc oncogene in a precursor B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. N Engl J Med 318:1373-1378, 1988.
124. Yano T, Jaffe ES, Longo DL, Raffeld M. MYC rearrangements in histologically progressed follicular lymphomas. Blood 80:758-767, 1992.
125. Bissonnette RP, Echeverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359:552-554, 1992.
126. Kagan J, Croce CM. Molecular biology of lymphoid malignancies. Ann Oncol 2(suppl.2):9-21, 1991.
127. Tycko B, Sklar J. Chromosomal translocation in lymphoid neoplasia: a reappraisal of the recombinase model. Cancer Cells 2:1-8, 1990.
128. Haluska FG, Finver S, Tsujimoto Y, Croce CM. The t(8; 14) chromosomal translocation occurring in B-cell malignancies results from mistakes in V-D-J joining. Nature 324:158-161, 1986.
129. Facer CA, Playfair JHL. Malaria, Epstein - Barr virus, and the genesis of lymphomas. Adv Cancer Res 53:33-72, 1992.
130. Nakagomi H, Dolcetti R, Bejarano MT, Pisa P, Kiessling R, Masucci MG. The Epstein - Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer 57:240-244, 1994.
131. Longnecker R. Biochemical and genetic studies of Epstein - Barr virus latent membrane protein 2. Leukemia 8:S46-S50, 1994.
132. Miller CL, Burkhardt AL, Lee JH, Stealey B, Longnecker R, Bolen JB, Kieff E. Integral membrane protein 2 of Epstein - Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 2(2):155-166, 1995.
133. Minarovits J, Hu LF, Marcsek Z, Minarovits Kormuta S, Klein G, Ernberg I. RNA polymerase III-transcribed EBER 1 and 2 transcription units are expressed and hypomethylated in the major Epstein - Barr virus-carrying cell types. J Gen Virol 73:1687-1692, 1992.